ARCA Biopharma, Inc. ABIO Balance Sheet

Arca biopharma, inc. (ABIO)

Balance Sheet / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Dec'10
ASSETS
Current assets:
Cash and cash equivalents
6,674	8,363	9,645	9,966	8,006	6,608	8,056	9,635	12,096	8,702	8,142	9,101	6,170	7,401	8,095	14,379	29,717	38,802	41,482	44,086	12,184	15,354	17,249	19,377	21,202	16,756	18,632	20,374	3,537	2,920	3,081	3,182	4,227	5,943	5,748	7,463	7,025
Marketable securities
-	-	-	-	-	-	-	-	-	3,050	7,809	6,906	13,041	13,762	15,373	11,979	910	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current assets
704	117	259	357	513	169	336	375	631	547	425	648	643	282	320	377	391	114	205	241	490	134	216	303	599	169	379	284	456	125	184	408	475	269	340	364	137
Total current assets
7,378	8,480	9,904	10,323	8,519	6,777	8,392	10,010	12,727	12,299	16,376	16,655	19,854	21,445	23,788	26,735	31,018	38,916	41,687	44,327	12,674	15,488	17,465	19,680	21,801	16,925	19,011	20,658	3,993	3,045	3,265	3,590	4,702	6,212	6,088	7,827	7,162
Right-of-use asset - operating
49	22	11	28	44	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	2,352	3,967	5,008	5,306	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Property and equipment, net
10	10	10	13	19	24	29	33	37	42	48	54	59	66	69	76	24	28	31	34	34	36	26	29	26	29	27	21	22	23	33	43	52	66	166	490	690
Other assets
24	24	24	24	24	24	24	24	24	24	497	587	676	766	855	816	580	630	679	754	553	608	548	831	828	130	100	104	124	144	164	183	204	224	244	264	304
Total assets
7,461	8,536	9,949	10,388	8,606	6,825	8,445	10,067	12,788	12,365	16,921	17,296	20,589	24,629	28,679	32,635	36,928	39,574	42,397	45,115	13,261	16,132	18,039	20,540	22,655	17,084	19,138	20,783	4,139	3,212	3,462	3,816	4,958	6,502	6,498	8,581	8,156
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
167	418	135	254	260	230	217	406	772	622	1,237	1,072	980	1,205	1,141	760	744	364	647	714	651	795	365	725	552	597	447	387	377	65	119	227	126	260	284	517	388
Payable for purchases of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,009	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued compensation and employee benefits
189	129	158	114	206	150	184	134	239	757	193	141	241	719	162	100	152	669	114	202	123	329	99	141	111	459	75	103	60	103	80	128	78	111	75	115	175
Accrued expenses and other liabilities
799	379	857	831	822	413	577	520	708	691	1,114	1,306	1,297	472	853	837	439	471	543	-	-	264	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses and other liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	440	359	-	374	351	457	446	247	257	383	121	63	141	357	350	270	339	506
Deferred rent, current portion
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	3	8	16	24	33	33	33	32	33	121
Total current liabilities
1,155	926	1,150	1,199	1,288	793	978	1,060	1,719	2,070	2,544	2,519	2,518	2,396	2,156	1,697	2,344	1,504	1,304	1,356	1,133	1,388	838	1,217	1,120	1,502	769	750	828	305	286	529	594	754	661	1,004	1,190
Deferred rent, net of current portion
-	-	-	-	-	-	4	9	15	20	25	30	35	39	43	47	-	-	-	1	1	3	3	2	1	1	-	-	-	-	0	593,000	8	16	25	32	195
Total liabilities
-	-	-	-	-	-	982	1,069	1,734	2,090	2,569	2,549	2,553	2,435	2,199	1,744	-	1,504	1,304	1,357	1,134	1,391	841	1,219	1,121	1,503	769	750	828	305	286	529	602	770	686	1,036	1,385
Commitments and contingencies
-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0
Stockholders’ equity:
Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2019 and 2018
-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	0	-	-	0	0	0	0	-	0	-	-	-	-	0	0	-
Common stock, $0.001 par value; 100 million shares authorized at March 31, 2020 and December 31, 2019; 1,594,070 and 1,594,070 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively
2	2	2	1	1	1	14	14	14	12	12	10	9	9	9	9	9	9	9	63	21	3	21	21	21	16	13	10	3	3	15	12	12	2	11	11	9
Additional paid-in capital
152,040	152,024	151,987	151,222	147,915	144,965	144,894	144,836	144,776	141,266	141,147	137,113	134,885	134,715	134,744	134,477	134,283	134,128	133,983	133,780	99,472	99,360	-	-	-	90,498	-	-	-	-	-	-	-	-	-	-	-
Accumulated other comprehensive loss
-	-	-	-	-	-	-	-	-	-2	-3	-5	-9	-19	-6	13	6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	99,188	99,027	98,835	-	90,343	90,287	72,373	70,898	70,315	69,502	69,425	69,404	67,845	67,756	65,072
Accumulated deficit
-145,736	-144,416	-143,190	-142,034	-140,598	-138,934	-137,445	-135,852	-133,736	-131,001	-126,804	-122,371	-116,849	-112,511	-108,267	-103,608	-99,714	-96,067	-92,899	-90,085	-87,366	-84,622	-82,011	-79,727	-77,322	-74,933	-71,987	-70,264	-69,065	-67,994	-67,154	-66,227	-65,081	-63,674	-62,044	-60,222	-58,310
Total stockholders’ equity
6,306	7,610	8,799	9,189	7,318	6,032	7,463	8,998	11,054	10,275	14,352	14,747	18,036	22,194	26,480	30,891	34,584	38,070	41,093	43,758	12,127	14,741	17,198	19,321	21,534	15,581	18,369	20,033	3,311	2,907	3,176	3,287	4,356	5,732	5,812	7,545	6,771
Total liabilities and stockholders’ equity
7,461	8,536	9,949	10,388	8,606	6,825	8,445	10,067	12,788	12,365	16,921	17,296	20,589	24,629	28,679	32,635	36,928	39,574	42,397	45,115	13,261	16,132	18,039	20,540	22,655	17,084	19,138	20,783	4,139	3,212	3,462	3,816	4,958	6,502	6,498	8,581	8,156